By Turna Ray
In recent years, the few drug developers in attendance at the annual Personalized Medicine Conference in Boston generally held the view that pharmacogenomics wasn't ready for prime time as a drug development strategy, but a survey of the drug industry presented at the same meeting this year showed that pharma is slowly changing its tune.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.